{"DataElement":{"publicId":"4360253","version":"1","preferredName":"Patient Oncotype DX Breast Cancer Assay Identifier","preferredDefinition":"A response for the 7 character identifier assigned to the person's Oncotype DX Breast Cancer Assay result.","longName":"2453382v1.0:4360252v1.0","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"2453382","version":"1","preferredName":"Patient Oncotype DX Breast Cancer Assay Identifier","preferredDefinition":"information related to the unique identifier for a patient/participant's Oncotype DX assay, a diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy.","longName":"PT_ONCOTPDX_ID","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2453380","version":"1","preferredName":"Oncotype DX Breast Cancer Assay Identifier","preferredDefinition":"Oncotype DX is a diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen. (from genomichealth.com):One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","longName":"C52159:C25364","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oncotype DX Breast Cancer Assay","conceptCode":"C52159","definition":"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Identifier","conceptCode":"C25364","definition":"One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0DDF0D1A-22CB-6548-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-03-01","modifiedBy":"ONEDATA","dateModified":"2006-03-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0DDF0D1A-22CC-6548-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-03-01","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4360252","version":"1","preferredName":"Oncotype DX Breast Cancer Assay Identifier","preferredDefinition":"The identifier assigned to the person's Oncotype DX Breast Cancer Assay result.","longName":"4360252v1.0","context":"ECOG-ACRIN","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"7","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4360251","version":"1","preferredName":"Oncotype DX Breast Cancer Assay Identifier","preferredDefinition":"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","longName":"C52159:C25364","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oncotype DX Breast Cancer Assay","conceptCode":"C52159","definition":"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Identifier","conceptCode":"C25364","definition":"One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC32FBE2-7317-E247-E040-BB89AD432360","latestVersionIndicator":"Yes","beginDate":"2014-06-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2014-06-19","modifiedBy":"ONEDATA","dateModified":"2014-06-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ACRIN:American College of Radiology Imaging Network","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC32FBE2-7328-E247-E040-BB89AD432360","latestVersionIndicator":"Yes","beginDate":"2014-06-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2014-06-19","modifiedBy":"TAYLORT","dateModified":"2015-07-13","changeDescription":"7/13/15 released/tt_6/19/14 curated to support breast trials. tt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3314482","version":"1","longName":"Type of Category","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"3314494","version":"1","longName":"Labs","context":"ECOG-ACRIN"},{"publicId":"10000047","version":"1","longName":"Pathology","context":"ECOG-ACRIN"},{"publicId":"3852732","version":"1","longName":"Disease Site","context":"ECOG-ACRIN"},{"publicId":"3314464","version":"1","longName":"Breast","context":"ECOG-ACRIN"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Oncotype DX Breast Cancer Ass","type":"Preferred Question Text","description":"Oncotype DX Breast Cancer Assay Result ID","url":null,"context":"ECOG-ACRIN"},{"name":"4112 Text","type":"Alternate Question Text","description":"GHI Requisition Number","url":null,"context":"ECOG-ACRIN"}],"origin":"ACRIN:American College of Radiology Imaging Network","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC32BE77-E09F-7CB2-E040-BB89AD4304CD","latestVersionIndicator":"Yes","beginDate":"2014-06-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2014-06-19","modifiedBy":"TAYLORT","dateModified":"2015-07-13","changeDescription":"7/13/15 released/tt_3-3-15 edit to draft new def and question text- tt_6/19/14 curated to support breast trials. tt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}